Magellan Health Inc. has entered into a credit agreement that provides unit Magellan Pharmacy Services Inc. with access to a $200 million delayed-draw term loan. The credit facility, which is expected to mature Dec. 29, 2017, is guaranteed by substantially all of the non-regulated subsidiaries of Magellan Health. The loan's base-rate borrowings have an interest rate equal to the sum of 0.625 percentage points plus the prime rate, or 0.5 percentage points above the overnight federal funds rate or the one-month Eurodollar rate plus 1.0 percentage point. In the case of Eurodollar rate loans, the interest rate is the sum of 1.625 percentage points plus the Eurodollar rate for the selected interest period. The proceeds of the facility will be used for working capital and general corporate purposes, including to fund acquisitions. The Bank of Tokyo-Mitsubishi UFJ Ltd., Citigroup Global Markets Inc., Compass Bank doing business as BBVA Compass, JPMorgan Chase Bank NA, Suntrust Robinson Humphrey Inc. and Wells Fargo Securities LLC entered into the credit agreement with Magellan Health.